SIGNAL PATH TRIAL
"At SignalPath, we've created a better research ecosystem - one that combines a network of premier, technology-enabled research sites with a best in class suite of clinical trial tools to address the pain points experienced by patients, sites and sponsors," said Brad Hirsch, MD, co-founder and Chief Executive Officer of SignalPath. By joining with Verily, SignalPath will be able to provide clinical research sites access to a quickly growing portfolio of resources, tools and trial opportunities that further strengthen its value proposition. SignalPath's robust technology infrastructure offers novel approaches to partners that can dramatically improve the costs, complexities and time associated with clinical trials.
SIGNAL PATH SOFTWARE
SignalPath's platform reduces fragmentation by leveraging a modern software architecture with a cloud-based platform in order to optimize management of a study site's clinical trials portfolio. SignalPath was founded in 2014 with a similar goal to change the way that clinical research is conducted, and a specific focus on building state-of-the-art software to improve efficiency for clinical research sites. In addition, the Baseline community now numbers more than 500,000 individuals who are interested in participating in clinical research and automatically matched with research opportunities that meet their interests and profiles. The Baseline platform enables better and faster clinical trial execution, improved data aggregation and analysis, flexible study options designed for decentralized and hybrid trials, and the ability to capture real-world data, such as that generated by novel sensors and biomarkers.
The acquisition will strengthen and expand Verily's existing clinical trial system and evidence generation platform, known as Baseline. Together, we will advance digital solutions to improve ease, quality, efficiency and speed in the current clinical trial paradigm." "It's our goal to modernize the way clinical trials are conducted for patients, researchers and sponsors alike. "Joining forces helps to accelerate and scale our shared vision, increase efficiency and lower costs in clinical trials, empower clinical research sites with world class technology, and ultimately bring medicines to patients faster," said Amy Abernethy, MD, PhD, President of Clinical Studies Platforms at Verily. SOUTH SAN FRANCISCO AND RALEIGH, NC - AUGVerily, an Alphabet company, and SignalPath today announced that they have entered into an agreement in which Verily will acquire SignalPath, a privately held company based in Raleigh that has developed the SignalPath platform, a clinical trial management system (CTMS) that improves the ease, quality and efficiency of conducting clinical research at study sites. The three transcription factors and their downstream target genes coordinately promote self-renewal and pluripotency.Acquisition Marks Alphabet Company's First Major Acquisition As Business Continues to Scale However, these signaling pathways converge towards the activation of a core transcriptional network that is similar in both groups and involves OCt4, Nanog and Sox2. On the other hand, human-type ES/iPS cells, which are in need of Activin and FGF signaling, are termed 'primed state'. They are mainly maintained under the control of LIF and BMP signaling. Conventional mouse-type ES/iPS cells are called 'naive state' cells. PSCs including ES cells and iPS cells are categorized into two groups by their morphology, gene expression profile and external signal dependence. iPS cells are generated by reprogramming somatic cells back to pluripotent state with defined reprogramming factors, Oct4, Sox2, Klf4 and c-Myc (also known as Yamanaka factors). ES cells are derived from the inner cell mass (ICM) of blastocyst-stage embryos. The types of PSCs known to date include embryonic stem (ES) and induced pluripotent stem (iPS) cells. Pluripotent stem cells (PSCs) are basic cells with an indefinite self-renewal capacity and the potential to generate all the cell types of the three germinal layers.
0 kommentar(er)
